This is a renewal application to further our investigation into the mechanism and significance of Bif-1-mediated Bax/Bak activation and mitochondrial morphogenesis in the context of tumorigenesis. Our studies have suggested that Bif-1 directly interacts with Bax in the mitochondrial outer membrane (MOM) and that both the physical and functional interactions between Bif-1 and Bax require the priming of monomer Bax by apoptotic stimuli that trigger Bax membrane recruitment, such as the BH3-only protein tBid. It appears that Bif-1 acts by promoting Bax homo-oligomerization rather than by facilitating Bax recruitment to the MOM. In addition, Bak activation is delayed as well in cells lacking Bif-1 during apoptosis. However, Bif-1 does not interact with Bak directly. Interestingly, our preliminary studies have demonstrated that Bif-1 selectively binds to the Bak inhibitor VDAC2. Bif-1, also known as endophilin B1, is a member of the endophilin protein family. Like other endophilins, Bif-1 is able to generate membrane curvature through its N-BAR domain, promoting Bax insertion into lipid bilayers. Moreover, Bif-1 has been shown to be required for fission of the MOM. Thus, we strongly suspect that Bif-1, in collaboration with BH3-only molecules, promotes Bax/Bak activation by altering the mitochondrial membrane shape. Moreover, Bif-1 and endophilin B2 (EndoB2) form stable heterodimers or tetramers in cells, suggesting that EndoB2 may also participate in the MOM remodeling associated with Bax/Bak activation during apoptosis. To further investigate the roles of endophilin B family proteins in Bax/Bak activation and mitochondrial morphogenesis, we propose the following Specific Aims: 1) To define the roles of Bif-1 and EndoB2 in the regulation of Bax/Bak activation, mitochondrial morphogenesis, and apoptosis;2) To determine whether Bif-1 interaction with VDAC2 plays a role in the regulation of Bak oligomerization, mitochondrial morphology, and apoptosis;3) To determine the roles of Bif-1 and EndoB2 in apoptosis, mitochondrial morphogenesis, and androgen-independent prostate cancer progression in mouse models under both physiological and pathological settings.
Accumulating evidence suggests that Bif-1 is a tumor suppressor candidate. Successful implementation of this research will not only gain novel insight into the molecular mechanisms underlying the processes of Bax/Bak activation, mitochondrial morphogenesis and androgen-independent prostate cancer development, but will also contribute to the establishment of new strategies for the prevention and treatment of cancer.
|Takahashi, Yoshinori; Tsotakos, Nikolaos; Liu, Ying et al. (2016) The Bif-1-Dynamin 2 membrane fission machinery regulates Atg9-containing vesicle generation at the Rab11-positive reservoirs. Oncotarget 7:20855-68|
|Muppidi, Avinash; Doi, Kenichiro; Edwardraja, Selvakumar et al. (2014) Targeted delivery of ubiquitin-conjugated BH3 peptide-based Mcl-1 inhibitors into cancer cells. Bioconjug Chem 25:424-32|
|Muppidi, Avinash; Doi, Kenichiro; Ramil, Carlo P et al. (2014) Synthesis of cell-permeable stapled BH3 peptide-based Mcl-1 inhibitors containing simple aryl and vinylaryl cross-linkers. Tetrahedron 70:7740-7745|
|Young, Megan M; Kester, Mark; Wang, Hong-Gang (2013) Sphingolipids: regulators of crosstalk between apoptosis and autophagy. J Lipid Res 54:5-19|
|Takahashi, Yoshinori; Hori, Tsukasa; Cooper, Timothy K et al. (2013) Bif-1 haploinsufficiency promotes chromosomal instability and accelerates Myc-driven lymphomagenesis via suppression of mitophagy. Blood 121:1622-32|
|Young, Megan M; Takahashi, Yoshinori; Khan, Osman et al. (2012) Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis. J Biol Chem 287:12455-68|
|Liu, Qiang; Wang, Hong-Gang (2012) Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors. Commun Integr Biol 5:557-65|
|Runkle, Kristin B; Meyerkord, Cheryl L; Desai, Neelam V et al. (2012) Bif-1 suppresses breast cancer cell migration by promoting EGFR endocytic degradation. Cancer Biol Ther 13:956-66|
|Muppidi, Avinash; Doi, Kenichiro; Edwardraja, Selvakumar et al. (2012) Rational design of proteolytically stable, cell-permeable peptide-based selective Mcl-1 inhibitors. J Am Chem Soc 134:14734-7|
|Watters, Rebecca J; Wang, Hong-Gang; Sung, Shen-Shu et al. (2011) Targeting sphingosine-1-phosphate receptors in cancer. Anticancer Agents Med Chem 11:810-7|
Showing the most recent 10 out of 37 publications